Altimmune Inc. Faces Class Action Lawsuit Following Disappointing Phase 2b Trial Results and Stock Plunge

Reuters

08/19

Altimmune Inc. Faces Class Action Lawsuit Following Disappointing Phase 2b Trial Results and Stock Plunge

A class action lawsuit has been filed against Altimmune Inc., a clinical-stage biopharmaceutical company based in Gaithersburg, Maryland. The lawsuit is on behalf of investors who acquired publicly traded securities of Altimmune between August 10, 2023, and June 25, 2025. The litigation follows Altimmune's announcement on June 26, 2025, regarding the topline results from its IMPACT Phase 2b trial of Pemvidutide for treating metabolic dysfunction-associated steatohepatitis (MASH). The company reported a failure to achieve statistical significance in the fibrosis reduction primary endpoint, attributing it to a higher-than-expected placebo response. This announcement led to a significant 53.2% drop in Altimmune's stock price. Investors affected during the specified period have until October 6, 2025, to seek to be appointed as lead plaintiff representatives in the class action.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Altimmune Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 262938) on August 18, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2560213882"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2560213882\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2560213882?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-19 03:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2560213882","market":"fut","top_or_hot":-1,"title":"Altimmune Inc. Faces Class Action Lawsuit Following Disappointing Phase 2b Trial Results and Stock Plunge","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Altimmune Inc. Faces Class Action Lawsuit Following Disappointing Phase 2b Trial Results and Stock Plunge\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        A class action lawsuit has been filed against Altimmune Inc., a clinical-stage biopharmaceutical company based in Gaithersburg, Maryland. The lawsuit is on behalf of investors who acquired publicly traded securities of Altimmune between August 10, 2023, and June 25, 2025. The litigation follows Altimmune's announcement on June 26, 2025, regarding the topline results from its IMPACT Phase 2b trial of Pemvidutide for treating metabolic dysfunction-associated steatohepatitis (MASH). The company reported a failure to achieve statistical significance in the fibrosis reduction primary endpoint, attributing it to a higher-than-expected placebo response. This announcement led to a significant 53.2% drop in Altimmune's stock price. Investors affected during the specified period have until October 6, 2025, to seek to be appointed as lead plaintiff representatives in the class action.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Altimmune Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 262938) on August 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Altimmune Inc. Faces Class Action Lawsuit Following Disappointing Phase 2b Trial Results and Stock Plunge</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAltimmune Inc. Faces Class Action Lawsuit Following Disappointing Phase 2b Trial Results and Stock Plunge\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-08-19 03:24</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Altimmune Inc. Faces Class Action Lawsuit Following Disappointing Phase 2b Trial Results and Stock Plunge\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        A class action lawsuit has been filed against Altimmune Inc., a clinical-stage biopharmaceutical company based in Gaithersburg, Maryland. The lawsuit is on behalf of investors who acquired publicly traded securities of Altimmune between August 10, 2023, and June 25, 2025. The litigation follows Altimmune's announcement on June 26, 2025, regarding the topline results from its IMPACT Phase 2b trial of Pemvidutide for treating metabolic dysfunction-associated steatohepatitis (MASH). The company reported a failure to achieve statistical significance in the fibrosis reduction primary endpoint, attributing it to a higher-than-expected placebo response. This announcement led to a significant 53.2% drop in Altimmune's stock price. Investors affected during the specified period have until October 6, 2025, to seek to be appointed as lead plaintiff representatives in the class action.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Altimmune Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 262938) on August 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4599","symbol_name":"減肥藥","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250818:nNDL638Gny:1","article_id":"2560213882","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2560213882","pubTimestamp":1755545056,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"A class action lawsuit has been filed against Altimmune Inc., a clinical-stage biopharmaceutical company based in Gaithersburg, Maryland. The lawsuit is on behalf of investors who acquired publicly traded securities of Altimmune between August 10, 2023, and June 25, 2025. The litigation follows Altimmune's announcement on June 26, 2025, regarding the topline results from its IMPACT Phase 2b trial of Pemvidutide for treating metabolic dysfunction-associated steatohepatitis . The company reported a failure to achieve statistical significance in the fibrosis reduction primary endpoint, attributing it to a higher-than-expected placebo response. This announcement led to a significant 53.2% drop in Altimmune's stock price. Investors affected during the specified period have until October 6, 2025, to seek to be appointed as lead plaintiff representatives in the class action.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT str","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4599":"减肥药","LU1878469433.USD":"THREADNEEDLE (LUX) - AMERICAN SMALLER COMPANIES \"A\" (USD) ACC","BK4139":"生物科技","ALT":"Altimmune, Inc."},"translate_title":"Altimmune Inc.因2b期试验结果令人失望和股价暴跌而面临集体诉讼","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALT":0.9},"content_text":"Altimmune Inc. Faces Class Action Lawsuit Following Disappointing Phase 2b Trial Results and Stock Plunge\n    \n\n        A class action lawsuit has been filed against Altimmune Inc., a clinical-stage biopharmaceutical company based in Gaithersburg, Maryland. The lawsuit is on behalf of investors who acquired publicly traded securities of Altimmune between August 10, 2023, and June 25, 2025. The litigation follows Altimmune's announcement on June 26, 2025, regarding the topline results from its IMPACT Phase 2b trial of Pemvidutide for treating metabolic dysfunction-associated steatohepatitis (MASH). The company reported a failure to achieve statistical significance in the fibrosis reduction primary endpoint, attributing it to a higher-than-expected placebo response. This announcement led to a significant 53.2% drop in Altimmune's stock price. Investors affected during the specified period have until October 6, 2025, to seek to be appointed as lead plaintiff representatives in the class action.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Altimmune Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 262938) on August 18, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"policyRegulatory,event","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}